Allen A. Thomas
Degrees
Ph.D., Organic Chemistry, May 2000
The Scripps Research Institute, La Jolla, CA
Advisor: K. Barry Sharpless, Ph.D., W.M. Keck Professor of Chemistry, 2001 Nobel Laureate in Chemistry
Dissertation: “I. Aminohydroxylation of Unsaturated Phosphonates: A Template for Molecular Diversity. II. Rapid Discoveries in Osmium (VIII) Catalysis Using Automation and Mass Spectrometry.”
M.S., Organic Chemistry, May 1994
Baylor University, Waco, TX
Advisor: Charles Garner, Ph.D., Professor of Chemistry and Graduate Program Director
Thesis: “Toward Terpene-Derived C2-Chiral Cyclic Boranes and Auxiliaries and Metalation Studies of Endocyclic and Exocyclic Alkenes.”
B.S., Chemistry, ACS Certified, May 1992
Baylor University, Waco, TX
Summa Cum Laude, Phi Beta Kappa, Highest Ranking Student in College of Arts and Sciences (GPA: 4.0/4.0)
Experience
University of Nebraska at Kearney
Department of Chemistry
Associate Professor (Aug 2018-present)
Assistant Professor (Aug 2014-18)
Areas of Interest: Bio-organic and medicinal chemistry; designing drugs that target the central nervous system (CNS); brain cancer; adenosine signaling; membrane transporter proteins.
Community College of Denver
Chemistry Instructor (2013-14)
Array BioPharma, Boulder, CO
Medicinal Chemistry
Senior Research Investigator (2012-13)
Research Investigator (2006-12)
Senior Research Scientist (2003-06)
Research Scientist (2000-03)
Optimization of small molecule drug candidates in multiple therapeutic areas including cancer, Alzheimer’s disease, pain, and inflammatory diseases. Collaborated within multidisciplinary teams to integrate data from in vitro and in vivo experiments to obtain an Erk inhibitor (GDC-0994, Ravoxertinib) for cancer that progressed to human clinical trials, and two compounds that advanced to pre-clinical toxicology studies (BACE/Alzheimer’s and Met/cancer). Highly skilled synthetic organic chemist having prepared thousands of compounds involving up to 14-step syntheses, including compounds with multiple chirality centers.
Management and mentoring of junior scientists, including written performance reviews and establishing semiannual goals. My associates were consistently outstanding contributors, and they were inventors and authors of multiple patents, presentations and publications.
Access Pharmaceuticals (now Abeona), Dallas, TX
Drug Delivery/Polymer Therapeutics
Scientist (1997-98)
Applied NMR and analytical chemistry techniques to determine the chemical structure of a cis-platinum conjugated polymer (ProLindac) that progressed to human clinical trials for cancer.